71455-51-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-CHLORO-BENZOYLAMINO)-BUTYRIC ACID is used as a pharmaceutical compound for its potential therapeutic uses. It may possess biological activities that can be harnessed for the development of new drugs and treatments.
Used in Organic Synthesis:
4-(4-CHLORO-BENZOYLAMINO)-BUTYRIC ACID is used as a building block in organic synthesis for the creation of various chemical compounds. Its unique structure, which includes a benzoylamino group and a chlorine atom, makes it a valuable component in the synthesis of new molecules with potential applications in various fields.

InChI:InChI=1/C11H12ClNO3/c12-9-5-3-8(4-6-9)11(16)13-7-1-2-10(14)15/h3-6H,1-2,7H2,(H,13,16)(H,14,15)/p-1

Upstream product

• 122-01-0 4-chloro-benzoyl chloride 
• 56-12-2 4-amino-n-butyric acid 
• 50-99-7 D-glucose 
• 74-11-3 para-chlorobenzoic acid 

Downstream Products

• 71455-62-4 N-(p-chlorobenzoyl)-4-benzylaminobutyric acid 
• 71510-66-2 benzyl N-(p-chloro)benzoyl-4-benzylaminobutyrate 

Relevant academic research and scientific papers

Aryl carboxylic acid reduction and further reactions with GABA and glucose promoted by whole cells of Xylaria arbuscula

Xylaria arbuscula was collected from a Cypress tree, Cupressus lusitanica. The whole cells of this endophytic fungus were used in screening for microbial bioreduction of aryl acids. Different p-substituted benzoic acids were evaluated. However, only p-bromobenzoic acid, p-chlorobenzoic acid and p-nitrobenzoic acid were converted to their corresponding alcohols. Aryl acid metabolism of X. arbuscula included GABA incorporation and glycosylation when the substrates were p-bromobenzoic and p-chlorobenzoic acids were also observed. The substrates p-hydroxybenzoic and p-aminobenzoic acids were not transformed. These results could suggest that electron-withdrawing groups at para orientation activate the substrate for reduction.

Acylhydrocarbylaminoalkanoic acids, compositions and uses

Compounds of the formula STR1 wherein R is (a) optionally-substituted and optionally-hydrogenated biphenylyl, (b) optionally-substituted and optionally-hydrogenated bicyclic aryl having from 8 to 12 ring carbon atoms or (c) a radical of the formula STR2 R1 is aliphatic hydrocarbyl, alicyclic hydrocarbyl or optionally-substituted phenyl; R2 is --H or lower aliphatic hydrocarbyl; R3 is --H, lower alkyl, cycloalkyl, optionally-substituted phenyl or, with R4, alkylene; R4 is lower alkyl, cycloalkyl, optionally-substituted phenyl, optionally-(nuclearly)-substituted phenalkyl or, with R3, alkylene; or R2,R3 and R4, together with the carbon to which each is bound, are adamantyl; and n is 3, 4 or 5; and salts thereof with a base are pharmacologically active. Esters thereof are valuable intermediates for the preparation of the pharmacologically-active compounds. Physiologically-acceptable embodiments are administered, e.g., in the form of an appropriate pharmaceutical composition to warm-blooded animals for protection against and treatment for stomach, intestine, pancreas, bile and liver disorders. Syntheses of pharmacologically-active components, transforming toxic embodiments to physiologically-acceptable principles, compounding such principles into pharmaceutical compositions and using such principles for preventing and treating the noted disorders are discussed.